Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

migrator

Updated:2nd Sep, 2021 at 6:28 PM

New Delhi

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

''Granules is working closely with DRDO team to launch the product in India at the earliest,'' it added. The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent, the filing said. Shares of Granules India closed at Rs 344.20 per scrip on BSE, down 0.22 percent from the previous close.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

SCROLL FOR NEXT

Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research &amp; Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Also Read

Power goes off at TVK EB Minister's event; he claims generator glitch, TNPDCL admits feeder fault

Tasmac gears up for fresh bar tenders in October, ‘spies’ on potential saboteurs

In lottery-less TN, fortune hunters wait for Keralam’s Rs 30 crore Onam bumper results on Sept 26

CM Vijay to visit Meenakshi Amman Temple on September 28 after launching TNTM scheme in Madurai

OpenAI says its models engaged with US government websites in new model misbehaviour disclosure

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).